Table 1.
Summary of Selected Clinical Trials of Microbe-Targeted Therapies in IBDs
| UC | CD | Pouchitis | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| Benefit | Trial Design | Benefit | Trial Design | Benefit | Trial Design | |
|
| ||||||
| FMT | − + |
RCT [18] Case Series [14,15] |
+ | Case Series [17] | ||
|
| ||||||
| Antibiotics | ||||||
| • Ciprofloxacin/Metronidazole | +/− | RCT [44,45] | + (colonic/perianal) | RCT [26–28] | + | RCT [52,53] |
| • Rifaximin | − | RCT [57] | + (colonic) | RCT [30] | − | RCT [54] |
| • Broad Spectrum | + | RCT [46,48] | ||||
|
| ||||||
| Probiotics | ||||||
| • VSL#3 | + | RCT [67,68] | − | RCT [74] | + | RCT [80,83] |
| • Other | − | RCT [66] | − | RCT [71–73] | − | RCT [85] |
|
| ||||||
| Prebiotics | − | RCT [93] | − | RCT [92,95] | − | RCT [96] |